ACTUALITES

SEMINARS

  • CRCL/CLB Seminar


The next CRCL/CLB seminar will take place Friday the 6th of October at 11.30am in the JL Requin meeting room (Cheney D, lower floor). We are pleased to welcome
Pr Harry Sokol (Head of the group "Microbiota and Immunity", UMR Micalis Inra-AgroParisTech). His talk will focus on: « Card9 is a key actor in gut microbiota modulation ».

SCIENTIFIC EVENTS

  • 3rd International CRCL Symposium

The 3rd CRCL Symposium took place in 25th-27th September 2017 ! Many thanks to our speakers, participants and sponsors, for their presence and support.

More information on our website available 
here.

The 2017 video will be available soon, meanwhile see the video of the 2015 edition below :
 

OTHER

  • A new International Associated Laboratory (LIA)


The CRCL team of Alain Puisieux "EMT and cancer cell plasticity"  sucessfully applied to an Inserm call to develop an International Associated Laboratory together with the group of Frederic Holland "Molecular mechanisms of tumor progression", from the Victorian Comprehensive Cancer Cancer, University of Melbourne, Australia.

LATEST PUBLICATIONS

  • A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability

Morel AP et al. Nature Medecine Avril 2017. The work presented in this publication was conducted by the of Alain Puisieux and his partners.

Chromosomal instability (CIN), a feature of most adult neoplasms from their early stages onward, is a driver of tumorigenesis. However, several malignancy subtypes, including some triple-negative breast cancers, display a paucity of genomic aberrations, thus suggesting that tumor development may occur in the absence of CIN. Here we show that the differentiation status of normal human mammary epithelial cells dictates cell behavior after an oncogenic event and predetermines the genetic routes toward malignancy. Whereas oncogene induction in differentiated cells induces massive DNA damage, mammary stem cells are resistant, owing to a preemptive program driven by the transcription factor ZEB1 and the methionine sulfoxide reductase MSRB3. The prevention of oncogene-induced DNA damage precludes induction of the oncosuppressive p53-dependent DNA-damage response, thereby increasing stem cells' intrinsic susceptibility to malignant transformation. In accord with this model, a subclass of breast neoplasms exhibit unique pathological features, including high ZEB1 expression, a low frequency of TP53 mutations and low CIN.
PubMed access: click here


  • A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability

This study involves the team of Patrick Mehlen. 
Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a mechanism to allow these tumors to escape the pro-apoptotic activity of some of its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2 domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts the interaction between netrin-1 and UNC5H2 and triggers death of netrin-1-expressing tumor cells in vitro. We also present evidence that combining the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in treating tumors showing no or modest netrin-1 expression. These results support that this antibody is a promising drug candidate.

PubMed access: click here

JOB OPPORTUNITIES

  • Octobre 2017

We are currently looking for postdoctoral researcher to join the “Activin Tumor Signaling” group of the Signaling, metabolism and tumor progression team headed by Ruth Rimokh/Germain Gillet at the Cancer Research Centre of Lyon (CRCL, France; http://www.crcl.fr). This team is part of the CRCL that will provide an excellent research environment including core facilities, support services as well as an international stimulating environment.
More information here

  • Octobre 2017

A two-year Post-doctoral Researcher position is available under the supervision of Dr. H Hernandez-Vargas, in the framework of two collaborating CRCL laboratories: the TGF-beta and Immune Evasion Group (Dr. J Marie), and the Hepatocarcinogenesis and Viral Infection Group (Dr. I Chemin).
More information here

  • Aout 2017

Chef de Projet RHU cirB-RNA.
Le programme du RHU cirB-RNA s’intègre dans la dynamique de recherche autour du virus de l’hépatite B, la détection et la prise en charge de la maladie, coordonnée par les Professeurs Zoulim et Levrero.
Plus d'informations

  • Aout 2017

We propose a post-doctoral position “Overcoming resistance to ibrutinib” for one and a half year in the team “Clinical and experimental models of lymphomagenesis” headed by Laurent Genestier & Gilles Salles. 
More information here 

  • Juin 2017

A post-doctoral position is available in the lab of Dr. G.Ichim for the study of mitochondrial regulation of cell death and non-lethal caspase activation.
More information here

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :
http://www.putainporno.com/videos-porno/porno-francais/ porno http://www.belloporno.com/channels/14/gay/page1.html